What’s Next for Clinical Decision Support Tools?
Sanofi Commits $1.7B to Buy an Entire Company, But Wants Just a Single Drug
The Weight Loss Market in 2024: 3 Key Questions We Can No Longer Ignore
Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned
Sarepta Gene Therapy Misses in Phase 3; Prospects Now Rely on FDA Flexibility
Eli Lilly Strikes $250M Deal to Add Gene-Editing Medicines for Cardio Conditions
MedCity Moves Podcast: Recent Hires, Layoffs & an Interview with Jeff Smith, CEO of Bamboo Health
The New Era of Programmable Biology
